Parkinson's Disease Neuroprotection Clinical Centers

帕金森病神经保护临床中心

• 批准号: 6659055
• 负责人: JOHN FANG
• 金额: $ 11.14万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6659055
• 关键词: Parkinson's disease; chemoprevention; clinical research; clinical trials; cooperative study; human subject; human therapy evaluation; nervous system disorder therapy; neuroprotectants; patient oriented research

DESCRIPTION (provided by applicant): As outlined in this RFA (RFA-NS-02-010) announcement, the aims of this project are to create a clinical center for the conduct of future clinical trials of neuroprotection for Parkinson's disease. This site has three board-certified neurologists trained in movement disorders who will participate in this proposed project. Upon implementation of this project these neurologists will collaborate to conduct a pilot trial of an agent to prevent disease progression in PD. Subsequently, additional collaboration with the other clinical center sites will lead to at least one multicenter trial. This project will help to maintain a stable infrastructure for the administration of the clinical trial(s) in neuroprotection related to Parkinson's disease. In addition, the conduct of this type of clinical trial(s) will generate a sample of patients with early PD who may be willing to participate in genetic studies. Similarly, subjects may be willing to participate in studies to identify markers from blood or cerebrospinal fluid that may indicate disease presence or severity. This research may lead to a greater understanding of PD and better treatments.

描述（由申请人提供）：如本RFA（RFA-NS-02-010）公告中所述，该项目的目的是为帕金森氏病神经保护的未来临床试验创建临床中心。该站点有三位接受运动障碍培训的董事会认证的神经科医生，他们将参加该拟议项目。实施该项目后，这些神经科医生将合作进行试剂试验，以防止PD疾病进展。随后，与其他临床中心站点的额外合作将导致至少一项多中心试验。 该项目将有助于维持与帕金森氏病有关的神经保护性临床试验的稳定基础设施。此外，这种类型的临床试验的行为将产生可能愿意参与遗传研究的早期PD患者样本。同样，受试者可能愿意参加研究，以鉴定可能表明疾病存在或严重程度的血液或脑脊液中的标记。这项研究可能会导致对PD和更好的治疗方法有更多的了解。